drugset / Trial / NCT03773744
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments. Upon determination of a Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) the study will be expanded into up to 24 additional Metastatic Melanoma patients.
Timeline
- Start
- 2020-02-15
- Primary completion
- 2020-10-30
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped: “insufficient suitable drug supply”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad-MAGEA3 | Vaccine | — | Intramuscular |
| Subject | MG1-MAGEA3 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |